ASA Srl of Arcugnano (VI) at MEDICA 2022 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Company news

Date

Topic

23 Aug 2022

Journal Of Inflammation Research: MLS® Laser Therapy and the consequences of interstitial pneumonia caused by COVID-19

The publication in the Journal of Inflammation Research entitled “Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial” highlights – within a clinical study – the legitimacy of Dr Sigman’s intuition and the validity of MLS® Laser Therapy on patients suffering from interstitial pneumonia caused by COVID-19.

The recent publication in the Journal of Inflammation Research reports that the effects on the patients were measured through blood tests, chest X-rays, oxygenation monitoring, and through validated scores – subjective and objective – for pneumonia. The results actually showed that patients undergoing MLS® Laser Therapy:
.1 had a rapid recovery;
.2 showed an improvement in pulmonary indices (score: SMART-COP, BCRSS, RALE and CAP);
.3 did not need intensive care or mechanical ventilation support;
.4 did not report any posthumous consequences 5 months after treatment.

More Less

23 Aug 2022

M8: First Use of PBMT in COVID-19

BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with lung inflammation and cytokine storm. Photobiomodulation therapy (PBMT) is a safe, non-invasive therapy with significant anti-inflammatory effects. Adjunct PBMT has been employed in treating patients with lung conditions. Human studies and experimental models of respiratory disease suggest PBMT reduces inflammation and promotes lung healing. This is the first time supportive PBMT was used in a severe case of COVID-19 pneumonia.

CONCLUSIONS: This report has presented supportive PBMT in a patient with severe COVID-19 pneumonia. Respiratory indices, radiological findings, oxygen requirements, and patient outcomes improved over several days and without need for a ventilator. Future controlled clinical trials are required to evaluate the effects of PBMT on clinical outcomes in patients with COVID-19 pneumonia.

More Less

Please log in

You must be logged in to use matchmaking